High Incidence Chronic Diseases Driving Viral Inactivation Testing Market

The global viral inactivation market was valued at USD 320.5 Million in 2016 and poised to grow at a CAGR of 12.3% between 2016 and 2021, to reach USD 573.0 Million in 2021

Download PDF Brochure Here: http://bit.ly/2y3dnoK

The Major Drivers For  Viral Inactivation Market :

Rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in life sciences industry. Increasing number of new drug launches, rise in chronic disease burden, and increasing government support for the pharmaceutical and biotechnology industries will also aid the growth of this market.

Target Audience for this Report:

• Viral inactivation product manufacturers and vendors
• Research associations related to pharmaceutical and biotechnological research
• contract research organizations (CROs)
• Various research and consulting firms
• Healthcare institutions
• Research institutes
• Distributors of viral inactivation equipment

Key Players :

Major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

About Report :

The application segments included in this report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Of these the vaccines and therapeutics application hold the highest share.The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.

To Know More : http://bit.ly/2jtcOBY